Reference health
Current advancements and future perspectives of immunotherapy in colorectal cancer research
67/67 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
12 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 67 checked references that resolve
resolves10.1016/j.immuni.2016.05.001
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
resolves10.1136/esmoopen-2018-000377
Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer
resolves10.1136/gutjnl-2015-310912
Global patterns and trends in colorectal cancer incidence and mortality
resolves10.1158/1078-0432.CCR-15-1696
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
resolves10.1080/2162402X.2016.1203498
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
resolves10.1016/j.memsci.2015.12.058
Selective transportation of charged ZnO nanoparticles and microorganism dialysis through silicon nanoporous membranes
resolves10.1039/C5RA11725A
Studies on varying n-alkanethiol chain lengths on a gold coated surface and their effect on antibody–antigen binding efficiency
resolves10.1200/JCO.2009.26.7609
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
resolves10.1634/theoncologist.2017-0034
DNA Polymerase ε Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity
resolves10.3390/cancers12040889
Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?
resolves10.1042/BSR20170945
Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies
resolves10.1073/pnas.0402840101
T cell receptor-ligand interactions: A conformational preequilibrium or an induced fit
resolves10.1038/s41575-019-0126-x
Immunotherapy in colorectal cancer: rationale, challenges and potential
resolves10.1002/cam4.2344
Clinicopathological and mutational analyses of colorectal cancer with mutations in the <i>POLE</i> gene
resolves10.1073/pnas.192461099
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
resolves10.1093/intimm/dxh194
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
resolves10.1136/esmoopen-2018-EACR25.433
PO-407 Exploring the inhibitory potential of napthoquinones against NF-κB pathway
resolves10.1016/j.cbi.2019.108725
Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells
resolves10.1200/JCO.2014.56.2025
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
resolves10.1155/2020/9037217
Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions
resolves10.18632/oncotarget.13207
Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer
resolves10.1158/1078-0432.CCR-12-2625
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
resolves10.1155/2018/9602540
Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management
resolves10.1172/JCI84940
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
resolves10.4049/jimmunol.161.11.5855
Differential Role of CTLA-4 in Regulation of Resting Memory Versus Naive CD4 T Cell Activation
resolves10.1016/j.clsc.2017.07.001
Immunosuppressive Agents and Their Role in Managing Immunotherapy Toxicities in Melanoma
resolves10.3389/fimmu.2019.00630
PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation
resolves10.1002/ijc.25481
Sex disparities in colorectal cancer incidence by anatomic subsite, race and age
resolves10.1371/journal.pmed.1001988
A Nested Case–Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)
resolves10.1200/JCO.2017.76.9901
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
resolves10.1016/S1470-2045(17)30422-9
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
resolves10.1038/mt.2010.272
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
resolves10.1007/s13193-017-0655-0
Colorectal Cancer in India: An Audit from a Tertiary Center in a Low Prevalence Area
resolves10.3389/fimmu.2019.01875
The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer
resolves10.1038/s41416-019-0599-y
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
resolves10.3389/fonc.2018.00086
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
resolves10.2217/mmt-2019-0005
Immunotherapy in Metastatic Melanoma: A Novel Scenario of new Toxicities and their Management
resolves10.1093/annonc/mdw235
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
resolves10.1136/gutjnl-2018-317592
Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years
resolves10.1016/j.pbiomolbio.2020.01.001
T cell receptors, mechanosensors, catch bonds and immunotherapy
resolves10.1155/2019/2368249
Tumour-Associated Macrophages (TAMs) in Colon Cancer and How to Reeducate Them
resolves10.1016/j.ymthe.2017.03.010
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
The 12 references without a DOI — listed, not checked
no DOI — not checkedReview of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer
no DOI — not checkedClinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)
no DOI — not checkedGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
no DOI — not checkedNivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor
no DOI — not checkedA review of cancer immunotherapy toxicity
no DOI — not checkedFRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells
no DOI — not checkedMSI-H: a truly agnostic biomarker?
no DOI — not checkedColorectal cancer statistics, 2020
no DOI — not checkedRandomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502)
no DOI — not checkedPhase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC)
no DOI — not checkedRecent insights into nanotechnology development for detection and treatment of colorectal cancer
no DOI — not checkedAdoptive cell therapy targeting neoantigens: a frontier for cancer research
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.ejphar.2020.173819"><img src="https://citestamp.com/citestamped/10.1016/j.ejphar.2020.173819/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.ejphar.2020.173819)